Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

NCT04207190 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Roswell Park Cancer Institute

Collaborators